Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation

Treatment of ALK-rearranged non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) is challenged by the almost inevitable emergence of therapeutic resistance. Different profiles of resistance mechanisms have been reported for the currently available ALK TKIs. The ALK C1156Y mutati...

Full description

Bibliographic Details
Main Authors: Chuangzhou Rao, Liangqin Nie, Xiaokang Wu, Xiaobo Miao, Ting Chen, Liuxi Chen, Dongqing Zhang, Quan Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
ALK C1156
crizotinib
alectinib
acquired resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.915502/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.915502/full

Similar Items